170 related articles for article (PubMed ID: 15249718)
21. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
[TBL] [Abstract][Full Text] [Related]
25. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
de Jong WK; de Jonge MJ; van der Leest AH; van Meerbeeck JP; Groen HJ
Lung Cancer; 2008 Jul; 61(1):123-8. PubMed ID: 18179842
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.
Schmittel A; Fischer von Weikersthal L; Sebastian M; Martus P; Schulze K; Hortig P; Reeb M; Thiel E; Keilholz U
Ann Oncol; 2006 Apr; 17(4):663-7. PubMed ID: 16423848
[TBL] [Abstract][Full Text] [Related]
30. Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Allendorf DJ; Bordoni RE; Grant SC; Saleh MN; Reddy VB; Jerome ML; Dixon PM; Miley DK; Singh KP; Robert F
Cancer Chemother Pharmacol; 2015 Nov; 76(5):949-55. PubMed ID: 26395450
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.
Naka N; Kawahara M; Okishio K; Hosoe S; Ogawara M; Atagi S; Takemoto Y; Ueno K; Kawaguchi T; Tsuchiyama T; Furuse K
Lung Cancer; 2002 Sep; 37(3):319-23. PubMed ID: 12234702
[TBL] [Abstract][Full Text] [Related]
32. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
[TBL] [Abstract][Full Text] [Related]
34. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
35. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
[TBL] [Abstract][Full Text] [Related]
36. A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Misumi Y; Nishio M; Takahashi T; Ohyanagi F; Horiike A; Murakami H; Kenmotsu H; Yamamoto N; Ishii M; Shimokawa T; Hida N; Okamoto H
Jpn J Clin Oncol; 2014 Feb; 44(2):116-21. PubMed ID: 24338555
[TBL] [Abstract][Full Text] [Related]
37. Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
Thiery-Vuillemin A; Dobi E; Nguyen T; Royer B; Montange D; Maurina T; Kalbacher E; Bazan F; Villanueva C; Demarchi M; Chaigneau L; Ivanaj A; Pivot X
Anticancer Drugs; 2010 Nov; 21(10):958-62. PubMed ID: 20856105
[TBL] [Abstract][Full Text] [Related]
38. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
40. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
